Tenax Therapeutics, Inc.

NasdaqCM:TENX Stok Raporu

Piyasa değeri: US$15.3m

Tenax Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Chris Giordano

İcra Kurulu Başkanı

US$644.8k

Toplam tazminat

CEO maaş yüzdesi62.9%
CEO görev süresi3.3yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi3.3yrs
Yönetim Kurulu ortalama görev süresi3.8yrs

Son yönetim güncellemeleri

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20
Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

CEO Tazminat Analizi

Chris Giordano'un ücretlendirmesi Tenax Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$645kUS$405k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$667kUS$386k

-US$11m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$861kUS$183k

-US$32m

Tazminat ve Piyasa: Chris's total compensation ($USD644.77K) is about average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Giordano (50 yo)

3.3yrs

Görev süresi

US$644,770

Tazminat

Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77kVeri yok
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Lawrence Hoffman
Interim Chief Financial Officerless than a yearVeri yokVeri yok
Doug Randall
Executive Vice President of Commercial & Business Operationsno dataVeri yokVeri yok
Douglas Hay
Senior Vice President of Regulatory Affairsno dataVeri yokVeri yok

3.3yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim: TENX's management team is considered experienced (3.3 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77kVeri yok
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Gerald Proehl
Independent Chairman10.6yrsUS$88.50k0.049%
$ 7.5k
Michael Davidson
Independent Director3.8yrsUS$57.50k0.085%
$ 12.9k
Daniel Burkhoff
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrsVeri yokVeri yok
Declan Doogan
Independent Director3.8yrsUS$48.50k0.067%
$ 10.2k
Robyn Hunter
Independent Director2.8yrsUS$65.00k0%
$ 0
June Almenoff
Independent Director3.8yrsUS$59.50k0%
$ 0
Sanjiv Shah
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrsVeri yokVeri yok
Barry Borlaug
Member of PH-Left Heart Disease Scientific Advisory Board4.8yrsVeri yokVeri yok
Robert Frantz
Member of PAH Scientific Advisory Boardno dataVeri yokVeri yok
Anna Hemnes
Member of PAH Scientific Advisory Boardno dataVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TENX's board of directors are considered experienced (3.8 years average tenure).